vs
德康医疗（DXCM）与WESTERN ALLIANCE BANCORPORATION（WAL）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是WESTERN ALLIANCE BANCORPORATION的1.2倍（$1.3B vs $1.0B），德康医疗净利率更高（21.2% vs 18.6%，领先2.7%），WESTERN ALLIANCE BANCORPORATION同比增速更快（31.0% vs 21.6%），过去两年WESTERN ALLIANCE BANCORPORATION的营收复合增速更高（14.9% vs 12.0%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
Western Alliance Bancorporation是总部位于美国菲尼克斯的区域性银行控股公司，长期深耕美国本土区域金融服务市场，目前已跻身美国最大银行行列，在福布斯发布的美国最佳银行榜单中排名第97位。
DXCM vs WAL — 直观对比
营收规模更大
DXCM
是对方的1.2倍
$1.0B
营收增速更快
WAL
高出9.4%
21.6%
净利率更高
DXCM
高出2.7%
18.6%
两年增速更快
WAL
近两年复合增速
12.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.0B |
| 净利润 | $267.3M | $189.2M |
| 毛利率 | 62.9% | — |
| 营业利润率 | 25.6% | — |
| 净利率 | 21.2% | 18.6% |
| 营收同比 | 21.6% | 31.0% |
| 净利润同比 | 153.6% | -5.0% |
| 每股收益（稀释后） | $0.67 | $1.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMWAL
| Q1 26 | $1.3B | $1.0B | ||
| Q4 25 | $1.3B | $980.9M | ||
| Q3 25 | $1.2B | $938.2M | ||
| Q2 25 | $1.2B | $845.9M | ||
| Q1 25 | $1.0B | $778.0M | ||
| Q4 24 | $1.1B | $838.4M | ||
| Q3 24 | $994.2M | $823.1M | ||
| Q2 24 | $1.0B | $771.8M |
净利润DXCMWAL
| Q1 26 | $267.3M | $189.2M | ||
| Q4 25 | $267.3M | $286.1M | ||
| Q3 25 | $283.8M | $253.4M | ||
| Q2 25 | $179.8M | $230.4M | ||
| Q1 25 | $105.4M | $199.1M | ||
| Q4 24 | $151.7M | $216.9M | ||
| Q3 24 | $134.6M | $199.8M | ||
| Q2 24 | $143.5M | $193.6M |
毛利率DXCMWAL
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
营业利润率DXCMWAL
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 36.3% | ||
| Q3 25 | 20.1% | 33.4% | ||
| Q2 25 | 18.4% | 34.4% | ||
| Q1 25 | 12.9% | 31.7% | ||
| Q4 24 | 17.0% | 30.9% | ||
| Q3 24 | 15.3% | 30.6% | ||
| Q2 24 | 15.7% | 32.1% |
净利率DXCMWAL
| Q1 26 | 21.2% | 18.6% | ||
| Q4 25 | 21.2% | 29.2% | ||
| Q3 25 | 23.5% | 27.0% | ||
| Q2 25 | 15.5% | 27.2% | ||
| Q1 25 | 10.2% | 25.6% | ||
| Q4 24 | 13.6% | 25.9% | ||
| Q3 24 | 13.5% | 24.3% | ||
| Q2 24 | 14.3% | 25.1% |
每股收益（稀释后）DXCMWAL
| Q1 26 | $0.67 | $1.65 | ||
| Q4 25 | $0.67 | $2.59 | ||
| Q3 25 | $0.70 | $2.28 | ||
| Q2 25 | $0.45 | $2.07 | ||
| Q1 25 | $0.27 | $1.79 | ||
| Q4 24 | $0.37 | $1.94 | ||
| Q3 24 | $0.34 | $1.80 | ||
| Q2 24 | $0.35 | $1.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | — |
| 总债务越低越好 | — | $4.3B |
| 股东权益账面价值 | $2.7B | $7.9B |
| 总资产 | $6.3B | $98.9B |
| 负债/权益比越低杠杆越低 | — | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资DXCMWAL
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $904.9M | — | ||
| Q4 24 | $606.1M | — | ||
| Q3 24 | $621.2M | — | ||
| Q2 24 | $939.2M | — |
总债务DXCMWAL
| Q1 26 | — | $4.3B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $436.0M |
股东权益DXCMWAL
| Q1 26 | $2.7B | $7.9B | ||
| Q4 25 | $2.7B | $7.7B | ||
| Q3 25 | $2.7B | $7.4B | ||
| Q2 25 | $2.6B | $7.1B | ||
| Q1 25 | $2.3B | $6.9B | ||
| Q4 24 | $2.1B | $6.7B | ||
| Q3 24 | $2.0B | $6.7B | ||
| Q2 24 | $2.4B | $6.3B |
总资产DXCMWAL
| Q1 26 | $6.3B | $98.9B | ||
| Q4 25 | $6.3B | $92.8B | ||
| Q3 25 | $7.5B | $91.0B | ||
| Q2 25 | $7.3B | $86.7B | ||
| Q1 25 | $6.8B | $83.0B | ||
| Q4 24 | $6.5B | $80.9B | ||
| Q3 24 | $6.4B | $80.1B | ||
| Q2 24 | $6.8B | $80.6B |
负债/权益比DXCMWAL
| Q1 26 | — | 0.54× | ||
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.07× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
